4.6 Review

Signaling Pathways of the Insulin-like Growth Factor Binding Proteins

Journal

ENDOCRINE REVIEWS
Volume 44, Issue 5, Pages 753-778

Publisher

ENDOCRINE SOC
DOI: 10.1210/endrev/bnad008

Keywords

IGF; IGF binding protein; signaling; receptor; cell-surface; nucleus

Ask authors/readers for more resources

The 6 high-affinity insulin-like growth factor binding proteins (IGFBPs) have diverse functions in cell signaling and can impact cell survival, migration, metabolism, and other cellular functions. They interact with multiple pathways and regulatory proteins, including integrins and transforming growth factor beta family receptors. IGFBPs can also regulate nuclear hormone receptors, senescence, DNA damage repair, and immune functions. Understanding the complexity of IGFBPs' interactions may provide therapeutic opportunities for modulating IGFBP-dependent signaling.
The 6 high-affinity insulin-like growth factor binding proteins (IGFBPs) are multifunctional proteins that modulate cell signaling through multiple pathways. Their canonical function at the cellular level is to impede access of insulin-like growth factor (IGF)-1 and IGF-2 to their principal receptor IGF1R, but IGFBPs can also inhibit, or sometimes enhance, IGF1R signaling either through their own post-translational modifications, such as phosphorylation or limited proteolysis, or by their interactions with other regulatory proteins. Beyond the regulation of IGF1R activity, IGFBPs have been shown to modulate cell survival, migration, metabolism, and other functions through mechanisms that do not appear to involve the IGF-IGF1R system. This is achieved by interacting directly or functionally with integrins, transforming growth factor beta family receptors, and other cell-surface proteins as well as intracellular ligands that are intermediates in a wide range of pathways. Within the nucleus, IGFBPs can regulate the diverse range of functions of class II nuclear hormone receptors and have roles in both cell senescence and DNA damage repair by the nonhomologous end-joining pathway, thus potentially modifying the efficacy of certain cancer therapeutics. They also modulate some immune functions and may have a role in autoimmune conditions such as rheumatoid arthritis. IGFBPs have been proposed as attractive therapeutic targets, but their ubiquity in the circulation and at the cellular level raises many challenges. By understanding the diversity of regulatory pathways with which IGFBPs interact, there may still be therapeutic opportunities based on modulation of IGFBP-dependent signaling. [GRAPHICS] .

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available